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ScienceDirectThe recent advances in cellular microbiology, genomics, and
immunology has opened new horizons in the understanding of
meningococcal pathogenesis and in the definition of new
prophylactic intervention. It is now clear that Neissera
meningitidis has evolved a number of surface structures to
mediate interaction with host cells and a number of
mechanisms to subvert the immune system and escape
complement-mediated killing. In this review we report the more
recent findings on meningococcal adhesion and on the
bacteria-complement interaction highlighting the redundancy
of these mechanisms. An effective vaccine against
meningococcus B, based on multiple antigens with different
function, has been recently licensed. The antibodies induced
by the 4CMenB vaccine could mediate bacterial killing by
activating directly the classical complement pathway or,
indirectly, by preventing binding of fH on the bacterial surface
and interfering with colonization.
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Introduction
Meningococcal meningitis and sepsis are devastating
diseases which still affect people with an incidence vary-
ing between 0.5 and 1000 cases/100 000 depending on the
epidemiological areas. The etiological agent is Neisseria
Meningitidis, a gram negative diplococcus and an obligate
human pathogen. Meningococcus colonizes the nasophar-
yngeal mucosa and is most typically carried asymptomati-
cally by approximately 10% of the population at any given
time [1]. Rates of asymptomatic carriage increase dramatic-
ally in certain conditions and at different ages, with a peak
in the adolescence, especially when people get together
such as at college and military entry. While colonization ofCurrent Opinion in Microbiology 2015, 23:68–72 the nasopharinx is a common event, the disease is rare but
can cause death or permanent disability in as little as
24 hours from the first recognizable symptoms [2].
To be able to colonize, survive in the bloodstream and
spread, the bacterium might use different strategies to
evade the immune system and to adapt to different
environments. Capsule is the main virulence factor and
its expression undergoes genetic regulation during patho-
genesis. Cell adhesion and biofilm formation are inhibited
by capsule and therefore the expression needs to be
downregulated or lost during carriage. On the other hand,
capsule is important for survival in the blood and is
consequently upregulated during invasion into the blood-
stream [2]. Twelve different meningococcal serogroups
have been defined based on the capsular polysaccharides
of which five: A, B, C, W135, and Y are responsible for the
majority of the disease, and with serogroup X more
recently identified as cause of sepsis and meningitis in
Africa [3]. The capsular polysaccharide represents the
major antigen and, in the case of A, C, W135, and Y is the
basis for the conjugate vaccines, shown to be very effec-
tive in preventing the disease in all age groups [2].
Serogroup B capsular polysaccharide is poorly immuno-
genic because it is identical to the polysialic acid present
in many human glycoproteins including the neural cell
adhesion molecule and as such cannot be used as vaccine
antigen [4]. The design of a broad protein-based vaccine
against meningococcus B had met numerous challenges.
The first protein based MenB vaccine contained outer
membrane vesicles (OMVs) and was shown to be effica-
cious against the OMV-derived strain. OMV protective
ability resides mainly in the PorA antigen, an integral
membrane protein with b-barrel structure and protruding
loops made by variable sequences which constitute the
main epitopes and which are the driving cause for the
OMV vaccine strain specificity [5].
This antigenic diversity of the meningococcal surface
proteins has been the main limitation in the design of
broadly protective meningococcal vaccines. The challenge
of the antigen diversity has been addressed by two differ-
ent approaches: one based on multiple antigens identified
by ‘reverse vaccinology’ which resulted in the develop-
ment of the first MenB vaccine licensed so far in Europe,
Australia, Canada and Chile (4CMenB) [6,7]; the other
based on the combination of two variants of the same
antigen and which is in late stage of development [8].
Here we will review the most recent findings in menin-
gococcal pathogenesis and on the mechanisms of immune
escape, with particular emphasis on the biological activitywww.sciencedirect.com
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Schematic illustration of Neisseria meningitidis outer membrane
proteins involved in colonization. App (adhesion and penetration
protein); Type IV pili; Opc (opacity protein C); NhhA (Neisseria hia/hsf
homologue); NadA (Neisseria adhesin A).of the antigenic components of the newly developed
MenB vaccines.
Meningococcal colonization
Adhesion to mucosal surface is an essential step in the
establishment of a carrier state. Acquisition of meningo-
coccus may be asymtomatic but in some circumstances
may result in local inflammation, invasion of mucosal
surfaces with access to the blood-stream which may result
in fulminant septicemia and/or meningeal inflammation.
The first step in meningococcal colonization is adhesion
to epithelial cells of the nasopharynx and is mediated by
Type IV pili, which are also involved in many stages of
the infection process, such as adhesion to endothelial
cells, bacterial aggregation, twitching motility, bacterial
migration and natural transformation [9]. They are multi-
meric proteins, with pilin E as the scaffold of the pilus
which spans the inner and the outer membranes and
extrudes through a pore formed by PilQ [10]. Over
20 proteins are required for a correctly assembled and
functional Type IV pilus [11]. PilE and PilV are involved
in adhesion to host cells and recently shown to activate
b2-adrenergic receptor (b2-AR), promoting the endo-
thelial signaling events enabling Neisseria translocation
through the brain endothelium [12,13]. The mechanism
of Type IV pili adhesion has been further elucidated by
Bernard et al. who identified CD147, a member of the
immunoglobulin (Ig) superfamily, as receptor for PilE
and PilV-mediated adhesion to human brain or peripheral
endothelial cells and shown the role of CD147 in vascular
colonization by meningococci [14]. However, the role
and the localization of some of the pili components is still
under discussion. Imhaus et al. recently demonstrated
that, despite the assigned function for pilX, as mediating
bacterial aggregation and for pilV as an adhesin, the two
pilus components are localized in the periplasm and very
interestingly, they exert their activity indirectly by chan-
ging the number of Type IV pili per bacterium and as
consequence, regulating competence, aggregation and
host-cell interaction [15].
Intimate adhesion is then mediated by the opacity
proteins, Opa, and Opc, with a typical integral membrane
protein structure, which bind to carcinoembryonic anti-
gen cell adhesion molecule (CEACAMs) receptor and
extracellular matrix components, respectively [16].
Although Pili, OpC, and Opa represent the most import-
ant and the most studied adhesins of meningococcus,
additional antigens have been described as having a role
in adhesion, such as NhhA (Neisseria hia/hsf homologue),
a trimeric autotransporter with homology to Hia and Hsf
adhesins of Haemophilus influenzae which binds to extra-
cellular matrix proteins, heparan sulfate and laminin and
facilitates attachment to host epithelial cells [17,18], App
(Adhesion and penetration protein, homologous to Hae-
mophilus Hap) [19,20] and NadA (Neisseria adhesin A), a
trimeric autotransporter belonging to the Oca familywww.sciencedirect.com (oligomeric coiled-coil adhesins) [21]. NadA expression
levels vary among isolates and is upregulated by niche-
specific signals via the transcriptional regulator NadR
[22], which binds the nadA promoter and represses tran-
scription. DNA-binding activity of NadR is attenuated by
4-hydroxyphenylacetic acid (4-HPA), a natural molecule
released in human saliva, thus leading to the de-repres-
sion of nadA in vivo [22]. NadA forms stable trimers on the
bacterial surface which mediate binding to epithelial cells
through interaction with a protein receptor molecule
differentially expressed by various epithelial cell lines
[23]. NadA interacts with Hsp90 (Heat shock protein 90),
and this influences its adhesive phenotype [24]. The
three dimensional structure reveals a novel TAA (trimeric
autotransporter adhesins) organization made mostly of a
coiled-coil with protruding wing-like structures forming a
head-like domain [25].
The presence in meningococcus of multiple adhesins
(Figure 1) with different receptor specificities suggests
that they could interact cooperatively with different
receptors on the same target cells, or may act at different
stages during infection, mediating Neisserial adhesion to
different cell types at different sites.
Although many aspects of the Neisseria pathogenesis
have been elucidated, and sophisticated in vitro and in
vivo systems are now available (tissue culture bilayers,
human nasopharynx transplantation, mice transgenic
for human receptors) to further explore the role of these
proteins in virulence and their potential as target for
therapeutic intervention, to be a promising vaccine
candidate, the antigen must induce complement-
mediated bactericidal antibodies, the established cor-
relate of protection in humans. In this respect, NadA is
the most promising vaccine candidate among the adhe-
sins identified so far, being able to induce high level of
bactericidal antibodies in humans and a component of
the 4CMenB vaccine.Current Opinion in Microbiology 2015, 23:68–72
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Antibodies are key in protecting against invasive menin-
gococcal infection. Goldshneider et al. demonstrated that
age disease incidence was inversely proportional to the
prevalence of bactericidal antibodies in the sera [26].
The complement system plays a major role in innate
immune defense against meningococcal disease and sub-
jects with terminal complement deficiencies are more
susceptible to invasive meningococcal disease [27].
There are three main complement pathways: the classi-
cal pathway (CP) which is mediated by the binding of the
C1 component to the antigen–antibody complex; the
lectin pathway which recognizes specific microbial pat-
terns composed of saccharides and related molecules and
the alternative pathway (AP) which is mediated by the
binding to C3 [28].
The three pathways involve the cleavage of C3, the
central component of the complement cascade, which
in turn induces the formation of the membrane attack
complex (MAC) and forming a pore in the membrane of
the target cell, induces cell death [28].
Factor H binding protein
In the last few years many proteins have been identified
as having a role in complement evasion. The most studied
is fhbp (factor H binding protein), also known as
GNA1870 [29] or rLP2086 [30], which interacts with
human Factor H, an inhibitor of the alternative comp-
lement pathway [31,32]. Fhbp is one of the antigenic
components of the licensed 4CMenB vaccine [7], or the
sole component of a vaccine under clinical development
[8]. The binding of fhbp to Factor H enhances menin-
gococcal serum resistance allowing the bacterium to grow
in the blood. The structure of fhbp or of fhbp-fh (domains
6 and 7) complex have been solved [33] and the residues
responsible for this interaction have been identified and
mutagenized to generate new non-fH binding with
enhanced immunogenicity in a fH transgenic mouse
model [34–37]. Interestingly, the side chains of fHbp
that interact with fH resemble the glycosaminoglycan
binding region of fH on host cells. Therefore Neisseria is
able, through fhbp, to recruit factor H by mimicking the
host [33].
Redundant complement escape mechanisms
More recently, a number of other surface-exposed anti-
gens able to inhibit the alternative complement pathway
have been identified, suggesting that the activity of fHbp
is not unique and that meningococcus possesses a variety
of mechanisms that enable it to evade the human
immune system. Additional bacterial components able
to bind factor H and inhibit the alternative complement
pathway are: NspA (Neisseria surface protein A), which,
like fhbp, binds domains 6 and 7 of human fH, and acts
cooperatively with fHbp [38,39]; PorB2 (Porin B2)Current Opinion in Microbiology 2015, 23:68–72 which binds not only human fH but also regulates the
alternative complement pathway of baby rabbit and
infant rat [40]; sialylated lipooligosaccharide (LOS)
which enhances the binding of fH C-terminal domains
18–20 to bacteria when C3 fragments are deposited on
the bacterial surface [39]. Moreover, Neisserial heparin
binding antigen (NHBA), an important component of the
4CMenB vaccine, is able to bind heparin in vitro through
an Arg-rich region and this property correlates with
increased survival of Neisseria in human blood [41].
Heparin is known to interact with many complement
components such as factor H, C4b-binding protein and
vitronectin. Therefore the establishment of the NHBA–
heparin complex on the meningococcal cell surface could
recruit complement inhibitors, and in turn prevent comp-
lement activation.
Capsular polysaccharides also modulate multiple path-
ways of the complement cascade. Serogroup Y and
W135 enhance activation of the AP by enhancing C3
activation and deposition. Moreover, Agarwal
et al. recently demonstrated that B, C, W, and Y capsular
polysaccharide inhibits the CP by inducing less C4b
deposition, limiting the ability of antibodies to mediate
bacterial killing. In this study, the different strains
showed different susceptibility to anti-fHbp antibodies
and complement, despite similar antibody binding to
the bacterial surface, suggesting possible implications
for the activity of fHbp-based vaccines [42]. PorA has
also been shown to bind C4b-binding protein (C4bp),
the major CP inhibitor. PorA-expressing strains were
more resistant to complement mediated lysis in a serum
bactericidal assay, suggesting that binding to C4bp
helps N. meningitidis to escape CP complement acti-
vation [43].
An additional mechanism to evade the complement sys-
tem is mediated by NalP, a serine protease autotranspor-
ter [44] which cleaves C3 four amino acids upstream from
the natural C3 cleavage site and produces shorter C3a-
like and longer C3b-like fragments. The C3b-like frag-
ment is degraded, resulting in lower deposition of C3b on
the bacterial surface which is then reflected in higher
meningococcal serum resistance [45].
Moreover, genes encoding for fhbp, LOS sialylation and
capsule biosynthesis are regulated by increase in
temperature, suggesting that this signal triggers menin-
gococcal immunoevasion and complement resistance
[46].
The evidence that N. meningitidis uses different mechan-
isms to subvert the complement system (Figure 2) and to
survive and multiply in the bloodstream, and the redun-
dancy in complement evasion mechanisms may have
important implications on meningococcal vaccines based
solely on one antigen.www.sciencedirect.com
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Schematic illustration of Neisseria meningitidis outer membrane proteins interacting with complement components. Capsule (capsular
polysaccharide); LOS (lipooligosaccharide); NalP (Neisseria autotransporter serine protease); porA (porin A); fhbp (factor H binding protein); NspA
(Neisseria surface protein A); porB2 (Porin B); NHBA (Neisserial heparin binding antigen).Future outlook
The evaluation of new meningococcal vaccines presents a
number of challenges. Studies on the evolution of menin-
gococcal pathogenesis, on the molecular epidemiology
and on the impact on complement evasion mechanisms
will be of primary importance during implementation of
such vaccines.
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